RESUMEN
Prazosin was compared with hydralazine in 39 patients (mean age 49 years), who were already on beta-blockade for arterial hypertension. They all had a resting DBP greater than 100 mm Hg on propranolol 80 mg b i d. They were randomly allocated to prazosin or hydralazine treatment. Blood pressure was measured after 4, 8 and 12 weeks. We noted a significant fall in blood pressure in both groups, in most cases to normotensive levels. Side-effects and other variables of interest are discussed. Together with beta blockade, i e propranolol, both prazosin and hydralazine give good blood-pressure control and no important differences could be found.
Asunto(s)
Hidralazina/uso terapéutico , Hipertensión/tratamiento farmacológico , Prazosina/uso terapéutico , Quinazolinas/uso terapéutico , Vasodilatadores/uso terapéutico , Adulto , Anciano , Ensayos Clínicos como Asunto , Método Doble Ciego , Resistencia a Medicamentos , Quimioterapia Combinada , Femenino , Humanos , Hidralazina/efectos adversos , Masculino , Persona de Mediana Edad , Prazosina/efectos adversos , Propranolol/uso terapéutico , Distribución AleatoriaRESUMEN
The definite demonstration that the microvascular complications of diabetes can be prevented by the normalization of blood glucose concentrations in man cannot be made since normoglycaemic cannot be sustained from the beginning of the disease with our current methods of treatment. Clinical studies despite their difficulties and limits seem to support the hypothesis that good control of diabetes at least in terms blood glucose is worthwhile. Some prominent scientists and physicians have questionned the validity of clinical studies and findings in animals and have asked whether the benefits of tight control have been sufficiently proven to warrant the risks of hypoglycaemia. Different groups of arguments have been given to support this point of view. The final answer to the question of whether blood sugar control prevents the complications of diabetes will probably come from the development of a technique for achieving perfect control of blood sugar for example with transplantation or an artificial pancreas.
Asunto(s)
Glucemia/metabolismo , Angiopatías Diabéticas/prevención & control , HumanosAsunto(s)
Presión Sanguínea/efectos de los fármacos , Hipertensión/tratamiento farmacológico , Prazosina/uso terapéutico , Quinazolinas/uso terapéutico , Renina/sangre , Adulto , Anciano , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Placebos , Prazosina/efectos adversos , Propranolol/uso terapéuticoRESUMEN
The effect of long-term treatment with phenformin and metformin respectively on blood lactate concentrations in relation to submaximal muscular exercise has been examined in 21 maturity-onset diabetics, using a cross-over method. At similar degrees of diabetic control the mean blood lactate concentration during exercise and shortly thereafter was significantly higher when the patients had received phenformin. The mean fasting lactate concentration was 1.07 mmol/l with phenformin and 1.03 mmol/l with metformin and the peak concentration was 2.56 mmol/l and 2.19 mmol/l respectively. The mean fasting blood glucose concentration before the exercise was 11.2 mmol/l with phenformin and 11.3 mmol/l with metformin; the glucose output in the urine during the preceding 24 hours was 93 mmol and 105 mmol respectively. The mean work load during exercise was 60 watts.